Patent intelligence · US
US 11421284
Methods for predicting drug responsiveness in cancer patients
Methods for predicting drug responsiveness in cancer patients
Patent details — US 11421284
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 23, 2022
- Expiration
- Aug 18, 2042
- Applicant
- Allarity Therapeutics Europe ApS
- Claims
- 20
- CPC classes
- A61K, A61K31/122, A61K45/06, A61K9/0019
Quick answer
US 11421284 (Methods for predicting drug responsiveness in cancer patients) is held by Allarity Therapeutics Europe ApS. Status: granted. Granted Aug 23, 2022. Expires Aug 18, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Allarity Therapeutics Europe ApS
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/122, A61K45/06, A61K9/0019
Frequently asked questions
What is US patent 11421284?
US 11421284 (Methods for predicting drug responsiveness in cancer patients) is held by Allarity Therapeutics Europe ApS. Status: granted. Granted Aug 23, 2022. Expires Aug 18, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11421284?
Allarity Therapeutics Europe ApS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11421284 expire?
Our index shows an expiration date of Aug 18, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.